New Research Identifies Enzyme Deficiency as Cause of Rare Skeletal Disorder
A groundbreaking study reveals that a deficiency in the enzyme TGDS leads to a rare skeletal disorder by disrupting glycosaminoglycan synthesis, offering new insights into diagnosis and treatment.
A recent study has shed light on the underlying cause of Catel–Manzke syndrome, a rare genetic bone disorder characterized by shortened bones, heart defects, cleft palate, and finger malformations. The research suggests that the syndrome stems from a deficiency of an enzyme known as dTDP-D-glucose 4,6-dehydratase (TGDS), leading to a shortage of an important enzyme-rescue metabolite.
Enzymes are crucial for facilitating various cellular processes, but they can become inactivated due to genetic mutations, environmental factors, or errors in cellular function. When enzymes like TGDS are inactivated, vital biochemical pathways are disrupted, which can result in developmental abnormalities.
The study discovered that TGDS plays a significant role in sugar metabolism related to bone formation. It appears that in humans, TGDS produces UDP-4-keto-6-deoxyglucose, a key molecule that helps maintain the function of another enzyme, UXS1, responsible for synthesizing UDP-xylose. UDP-xylose is essential for producing glycosaminoglycans (GAGs), structural components necessary for healthy skeletal development.
Researchers observed that if TGDS is inactivated, the production of UDP-4-keto-6-deoxyglucose declines, impairing UXS1 activity and reducing UDP-xylose levels. This reduction hampers GAG synthesis, ultimately affecting bone growth and leading to the symptoms observed in Catel–Manzke syndrome.
Experimental evidence from both cell cultures and mouse models supported this hypothesis. Mice with inactivated TGDS exhibited signs similar to human patients, confirming the enzyme's critical role in skeletal development.
The study concluded that TGDS is vital for producing UDP-4-keto-6-deoxyglucose, which helps counteract the inactivation of UXS1 in a cell-specific manner. While further research is needed to develop diagnostic and therapeutic applications, understanding this pathway paves the way for improved management of the disorder and potentially other enzyme-related diseases.
These findings advance our understanding of the molecular basis of rare skeletal disorders and may facilitate better genetic diagnosis and counseling in the future, highlighting the importance of enzyme rescue metabolites in human development.
Source: https://medicalxpress.com/news/2025-08-rare-bone-disorder-deficiency-enzyme.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Addressing Critical Gaps in Dementia Care and Childhood Cancer Support
Innovative research identifies key gaps in support systems for dementia and childhood cancer, emphasizing the need for accessible transportation and systematic social screening to improve patient care and quality of life.
New Research Highlights Increased Risk of Anal Cancer in Women with Prior Cervical Cancer
New research indicates women with a history of cervical cancer face a nearly doubled risk of developing anal cancer, highlighting the need for updated screening guidelines to improve early detection and prevention.
Artificial Intelligence Enhances Detection of High-Risk Colon Polyps
Artificial intelligence is revolutionizing colonoscopy by enabling even less experienced doctors to accurately identify dangerous colon polyps, improving early detection and prevention of colorectal cancer.
Revolutionizing Health Monitoring: 3D-Printed Wearable Devices Track Skin Gases Without Adhesives
A pioneering 3D-printed, adhesive-free wearable device monitors skin gases to provide continuous health data, offering new possibilities in long-term health tracking without skin irritation or sensor clogging.